We retrospectively evaluated 75 allogeneic stem cell transplant recipients to ascertain the incidence, risk factors and outcome of infection with Clostridium difficile. Ten patients (13%) had Clostridium difficile infection at a median of 38 days (range day −6 to day +72) following the transplant. There was no difference in the duration or severity of diarrhoea in patients with Clostridium difficile infection compared to the uninfected patients and no relationship to the prior antibiotic or chemotherapy usage, age, gender, underlying disease, donor type, CMV serostatus, total body irradiation or time to engraftment. The incidence of viral infections was increased in patients infected with Clostridium difficile (7/10 vs 15/65, P = 0.005, odds ratio 7.7), but the strongest association was with GVHD Ͼgrade 2 (5/10 vs 6/65 uninfected patients, P = 0.004, odds ratio 9.8). Patients infected with Clostridium difficile also suffered a higher non-relapse mortality with 7/10 patients succumbing to either GVHD or infections, compared to 19/65 patients in the uninfected group (P = 0.02, odds ratio 5.6). Thus Clostridium difficile infections in our study had a strong association with GVHD and increased non-relapse mortality. It is possible that Clostridium difficile toxin might predispose to increased severity of GVHD leading to an adverse outcome. Bone Marrow Transplantation (2000) 26, 871-876.
one study only. 3 This report identified an increased mortality in patients with C. difficile and enteric viral infections and also a trend towards increased GVHD which was not statistically significant. Although recent studies have examined this issue in autologous transplants 6, 7 without identifying any definite risk factor, the literature on C. difficile in allogeneic HSCT recipients remains scanty.
We retrospectively evaluated C. difficile infection in HSCT recipients in order to ascertain the incidence, risk factors and outcome.
Patients and methods
We evaluated the data on 75 patients who were treated in the BMT unit at Birmingham Heartlands Hospital for allo-SCT between January 1994 and October 1999. All the patients were nursed in single rooms with high efficiency particulate air (HEPA) filters. Conditioning treatment consisted of cyclophosphamide and total body irradiation (TBI) in 50 patients and busulfan cyclophosphamide in 13 patients. Twelve patients received a non-myeloablative schedule consisting of fludarabine, melphalan and Campath 1H.
Anti-microbial prophylaxis consisted of oral fluconazole, ciprofloxacin and oral aciclovir (ACV) from the beginning of conditioning treatment until engraftment. All patients received co-trimoxazole prophylaxis for Pneumocystis carinii infection. The 21 unrelated (UD) grafts and 20 matched sibling PBSC grafts were T cell-depleted by Campath 1G or 1H either in vitro or in vivo. Graft-versus-host disease (GVHD) prophylaxis for the remainder was cyclosporin A alone or with short course methotrexate. Thirty-five consecutive patients from 1998 onwards received metronidazole 400 mg three times a day from the day of transplant to engraftment for anaerobic decontamination as a part of GVHD prophylaxis; 8 29 of these patients received a T celldepleted graft.
Allograft recipients at risk of cytomegalovirus (CMV) disease (recipient or donor positive for CMV IgG) received prophylaxis with ganciclovir (500 mg/m 2 three times weekly after engraftment to 100 days post-transplant) or pre-emptive therapy with ganciclovir (GCV) (5 mg/kg twice daily) with or without foscarnet (120-180 mg/kg/day) based on a PCR assay. CMV sero-negative patients received blood products from CMV negative donors. The severity of gastro-intestinal symptoms was graded accord-ing to WHO toxicity criteria. GVHD was defined and graded according to standard criteria. 9 All patients with diarrhoea had faecal specimens assayed for C. difficile toxin. In addition, the samples were cultured for other bacterial, fungal and viral pathogens. C. difficile infection was diagnosed only in the presence of a positive toxin assay.
C. difficile toxin assay: C. difficile toxin B was detected by incubation of stool filtrates with human epithelial cells. Specifically, 0.5 ml of faecal specimen was added to 0.5 ml of foetal calf serum containing penicillin, gentamicin and amphotericin B. Following centrifugation for 10 min, 100 l of the supernatant was transferred to each of two wells of a microtitre plate: one with Hep 2 cells and the other containing Hep 2 cells along with Clostridium sordelli antitoxin. These were then incubated at 37°C overnight and observed the following morning for the presence of cytopathic effects of the cell layer, the second well acting as a control for non-specific cytopathic effects. Equivocal results from this assay were confirmed or refuted by toxin A enzyme-linked immunoassay.
Statistical methods
Univariate P values and odds ratios were calculated from 2 × 2 contingency tables using Epi info version 6 (CDC, Atlanta, GA, USA). A multiple logistic regression model was fitted to the data using a stepwise approach using the statistical programme of SPSS version 9 for windows (SPSS UK, Worthing, UK) for risk factor analysis. Survival probabilities were analysed by the Kaplan-Meier method and the difference between the groups was compared using log rank 2 test. The effect of the variables on non-relapse mortality were tested in a Cox regression model using the SPSS version 9.
Results
Ten patients (13%) developed C. difficile infection at a median of 38 days post-transplant (range day −6 to day +72) ( Table 1 ). The median age of these patients was 38 years (range 17-51 years). Eight of them had severe diarrhoea (WHO 3-4), four with abdominal cramps and blood in stool. The median duration of diarrhoea was 12 days (range 7-30). The median number of intravenous antibiotics used in the previous 8 weeks per episode of C. difficile infection was three (range 2-6). All patients received metronidazole as the first-line treatment. Five patients had a recurrence of C. difficile infection, three of them having more than one recurrence. Four patients with recurrent C. difficile infection and one patient with persistent infection required treatment with vancomycin. However, none developed any surgical complication and all responded to medical treatment. The median duration of treatment for each episode was 7 days (range 7-15 days).
There was no difference in the incidence of diarrhoea in the cohort of patients without C. difficile infection (10/10 vs 60/65). The incidence of Ͼgrade 2 diarrhoea did not differ either (8/10 vs 49/65). The median time to engraftment (neutrophils Ͼ0.5 × 10 9 /l) was similar in both groups (15 days) ( Table 2 ). There was also no relationship to the age, gender, underlying diagnosis, conditioning regimen, type of graft, and duration or type of antibiotic therapy. Patients receiving short course methotrexate as GVHD prophylaxis were not more likely to develop C. difficile infection (8/53 vs 2/22 patients not receiving methotrexate, P = 0.7).
Although the overall incidence of GVHD was not statistically significant in patients with C. difficile infections (6/10 vs 22/65, P = 0.09), severe GVHD (grade 3-4) had a significant association with C. difficile infections (5/10 vs 6/65, P = 0.004, OR 9.8). Four of these patients had GVHD of the gut. In three patients GVHD was preceded by C. difficile infection by 2-3 days ( Table 1 ). The remainder had the infection 5-32 days after the onset of GVHD, but in all cases this was associated with an increase in the severity of the GVHD. Also, among patients with C. difficile infection, recurrence was more common in patients with GVHD, although this was not statistically significant (4/6 vs 1/4 without GVHD, P = 0.5).
The use of prophylactic metronidazole had no significant impact on the incidence of C. difficile infections. Four out of 35 patients receiving metronidazole prophylaxis developed C. difficile infections compared to six out of 40 patients not receiving any anti-anaerobic treatment (P = 0.7).
Viral infections other than CMV were more common in patients with C. difficile infection (7/10 vs 15/65 in uninfected patients, P = 0.005, OR 7.7). Five patients had HSV infections, four of them resistant to antiviral drugs (vs 3/65 patients without C. difficile, P = 0.004, OR 13.7, CI 1.7-110). Two more had adenovirus infections, one of them (UPN 55) with concomitant infection with other respiratory viruses. However there was no relationship of C. difficile infections with the CMV sero-status or the dose/duration of antiviral therapy.
Overall mortality was higher in the patients with C. difficile infection, (8/10 vs 27/65, P = 0.03, OR 5.6). The non-relapse mortality was also significantly higher in C. difficile infected patients (7/10 vs 19/65, P = 0.02, OR 5.6). Four patients succumbed to GVHD and related complications. Three others died of viral infections. The median survival of the patients with C. difficile infection was only 100 days compared to 41 months in the patients without C. difficile (Figure 1 , log rank test significant at 0.01). The median survival of the patients without GVHD or C. difficile was 38 months and that for patients with GVHD, but without C. difficile 23 months, which was not statistically significant. Amongst patients with grade 3-4 GVHD, there was no difference in the incidence of viral infections (4/5 vs 3/6) and mortality (5/5 vs 6/6) between patients with and without C. difficile infections.
On a multiple logistic regression model, GVHD grade 3-4 was the only risk factor for C. difficile isolation (OR 9.8, CI 2.1-43). The variables analysed for their impact on non-relapse mortality were age, gender, diagnosis, donor type, use of TBI, engraftment, CMV sero-status, resistant HSV and C. difficile. Analysing these predictors in the Cox regression model by forward-conditional method, antiviral resistant HSV infection was the most important factor (risk ratio 4.8, CI 2.0-11.5). C. difficile infection (risk ratio 2.8, 
Discussion
C. difficile accounts for about 15-25% of cases of antibiotic-associated diarrhoea. 1 Recent studies have reported C. difficile infection in about 5-7% of autologous transplant recipients, 6 ,7 but few studies have addressed this in the setting of allogeneic transplants. In a prospective study of post-transplant diarrhoea in 296 allogeneic HSCT patients, C. difficile was isolated in only 6/126 (4.8%) patients with diarrhoea. 4 Another study on the faecal flora in 12 children undergoing BMT, C. difficile was isolated in 14% of diarrhoeal episodes. 5 Both studies looked at gut GVHD alone and did not address the final outcome of the patients. In these studies, the data on C. difficile was analysed in conjunction with other enteric pathogens. In a similar study, Yolken et al 3 detected C. difficile in 12/78 (15%) allogeneic HSCT patients. The incidence of GVHD was increased in the patients with enteric pathogens (C. difficile and enteric viruses) and the mortality was increased four-fold. However, the impact of C. difficile alone was not apparent from these studies.
In our study, C. difficile infection was detected in 13% of allogeneic HSCT recipients. Although the majority had severe diarrhoea, this was not a discriminant factor, as diarrhoea of non-infectious aetiology was common after HSCT. We found no correlation with antibiotic therapy or type of conditioning therapy. Methotrexate and fluorouracil have been incriminated most frequently in anti-neoplasticassociated C. difficile infection. 2 However, the use of short course methotrexate in our study was not associated with an increased incidence of C. difficile infection.
The only significant association with C. difficile infection in this study was GVHD grade 3-4. In patients infected with HIV, a CD4 + cell count of less than 50/mm 3 was found to be a risk factor for C. difficile infection. 10 GVHD and its treatment might similarly predispose to C. difficile infections. A number of studies have shown that inadequate immune response predisposes to severe and recurrent C. difficile infection. 11 In our study recurrent C. difficile was more common in patients with GVHD, although all responded to drug therapy. Whereas it is possible that GVHD might have predisposed to C. difficile infections, the reverse could also be true. Interestingly, three patients in our study developed GVHD just a few days after C. difficile infection and in the other three, the onset of C. difficile infection was followed by an increase in the severity of GVHD. A recent randomised study demonstrated a reduction in the severity of GVHD by anaerobic decontamination with metronidazole. 12 The present pathophysiologic concept of acute GVHD hinges on the stimulation of the allo-reactive lymphocytes by the dysregulation of proinflammatory cytokines in the early post-transplant period, induced by high-dose chemo-radiotherapy. 13, 14 The release of cytokines such as tumour necrosis factor-␣ (TNF-␣) is promoted by bacterial breakdown products like lipopolysaccharide (LPS). 15 TBI results in both increased circulation of LPS and increased sensitivity of macrophages to LPS. Complete decontamination of the intestine has been shown to prevent GVHD in experimental animals, possibly by abrogating the synergism between conditioning-induced cytokine dysregulation and release of bacterial breakdown products. 8, 12, 14, 16 C. difficile produces two toxins (toxins A and B) in its vegetative form, both of which are cytotoxic to human intestine epithelial cells. Both toxins have been shown to stimulate hepatocyte acute phase protein synthesis in vitro 17 and TNF-␣ has been shown to mediate the cytotoxicity of toxin A. 18 It is possible that C. difficile toxins aggravate GVHD by increasing the release of TNF-␣ and related proteins and thus promoting the cytokine dysregulation induced by high-dose chemo-radiotherapy. In addition, C. difficile toxins may augment the bacterial penetration of intestinal epithelium 19 and further trigger the cascade of GVHD.
Consistent with this hypothesis, C. difficile isolation was temporally associated with the onset or aggravation of GVHD in 60% of the infected patients in our study. It was not associated with a higher incidence of GVHD, but with an increase in the severity of GVHD. Whilst the effect on intestinal GVHD might be more direct, the effect on liver or cutaneous GVHD may be mediated either by increased systemic release of toxins or upregulation of MHC and adhesion molecules on the antigen-presenting cells in these organs leading to allo-specific donor T cell activation. 20 In a previous study, GVHD was shown to be more common in patients with C. difficile or enteric viruses, but the association was not statistically significant. 2 Pre-operative use of metronidazole reduces colonisation by C. difficile in patients undergoing gut surgery. 21 In the German study, 12 the anaerobic bacterial load correlated with the severity of GVHD and metronidazole effectively reduced their growth. Although we have used metronidazole over the last 2 years, this has not resulted in a significant reduction in the incidence of C. difficile infections. This could possibly be due to use of the drug for a shorter period than the above study, resulting in less effective decontamination of the gut. We have routinely T celldepleted the grafts almost in parallel with the introduction of metronidazole as GVHD prophylaxis (29/35 patients). This has resulted in a dramatic reduction of GVHD уgrade 2, making it difficult to ascertain the impact of metronidazole on the occurrence or severity of GVHD. However the only instance of grade 2 GVHD (UPN 49) in these 24
Bone Marrow Transplantation patients receiving T cell-depleted graft was associated with C. difficile.
The increased incidence of viral infections in these patients was possibly an indication of the underlying immunosuppression rather than a cause-effect relationship. In parallel with a previous study 3 the non-relapse mortality was higher in patients with C. difficile. The median survival of the patients was just 100 days. Although C. difficile was not the immediate cause of death in any of these patients, it may have contributed by aggravation of GVHD. The survival in patients with GVHD without C. difficile infection was not significantly different from patients without GVHD, suggesting GVHD alone was not responsible for the poor outcome. On the other hand, the occurrence of C. difficile itself might be a surrogate marker for an impaired immune system as evidenced by increased viral infections and an adverse outcome. Whether C. difficile has a direct impact on the worsening of the immune system is currently unclear. Further prospective studies are needed to delineate the exact relationship between C. difficile infection and GVHD.
